Symberix is developing microbiome-targeted small molecule drugs to treat gastrointestinal diseases. Gut dysbiosis occurs when there is an imbalance of good versus bad microbes in the gut and can contribute to a variety of human diseases. Symberix is identifying small molecules that can effectively inhibit the harmful activities of gut bacteria without killing beneficial microbes. Through this approach, Symberix has created a library of novel, potent bacteria-selective beta-glucuronidase (GUS) inhibitors. GUS activity in the gut microbiota is linked with intestinal inflammation and Symberix is advancing their lead candidate, SBX-101 to provide treatment options for patients with inflammatory bowel disease.

Symberix

Founded: 2015
Location: Durham, NC
Employee range: 1 - 10
Clinical stage: Clin0
Therapy area: Intestinal toxicities from antineoplastic agents, NSAIDs, and immunosuppressants
Drug types: GI, TOX
Lead product: SBX-101
Funding: not disclosed

Drug notes:

About:

Jobs: